The more potent later-generation TKIs allow for greater reductions in the level of BCR-ABL1 mRNA [5, 8], which is prognostic for event-free survival, progression-free survival and overall survival in CML [1, 2, 13, 14]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.